Paolo Tarantino

42PUBLICATIONS
117CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsOther Asian languages (excl. South-East Asian)Glycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jul 13, 2026
Recurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health records study.

|Mar 16, 2026
Antibody-drug conjugates in breast oncology: new standards, emerging challenges, and future directions.

Prarthna V Bhardwaj, Paolo Tarantino, Ilana Schlam

|Feb 06, 2026
Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer.

Tess A O'Meara, Paolo Tarantino

|Jan 23, 2026
Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Paolo Tarantino

|Dec 19, 2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.

Amin H Nassar, Elias Bou Farhat, Hassan Abushukair

|Nov 08, 2025
Response to Orlandi.

Paolo Tarantino, Do Lee, Pamela R Soulos

Pageof 7

Frequent Collaborators

17 joint publications

Sara M Tolaney

12 joint publications

Giuseppe Curigliano

6 joint publications

Ilana Schlam

5 joint publications

Filipa Lynce